You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Bio-Rad said it is withdrawing its previously issued annual revenue guidance given the uncertainties regarding the duration and impact of the COVID-19 pandemic.
The firm said it can produce enough viral RNA extraction reagents to support more than 7 million real-time PCR tests per month for detecting SARS-CoV-2.
For the three months ended Mar. 31, the firm reported total revenues of $31.1 million compared to $29.5 million in Q1 2019, beating analysts' average estimate of $30.6 million.
The company's revenues for its 4Kscore prostate cancer test were impacted partially by the COVID-19 pandemic, Opko said.
The firm's influenza testing revenue reached record highs in January and February, and continued at a high level throughout the end of the quarter.
The firm said international sales of its OraQuick HIV products increased 74 percent year over year, driven by sales of its OraQuick HIV Self-Test.
Natera reported $94 million in revenues for the quarter, up from $66.8 million a year ago and beating analysts' consensus estimate of $85 million.
The company said the funds will support the continued development and commercialization of its genome-wide methylation assay for multi-cancer early detection.
The firm reported that revenues from screening products rose 35 percent year over year to nearly $220 million.
The oral MET inhibitor, marketed as Tabrecta, is for patients whose tumors have a mutation that leads to MET exon 14 skipping as detected by a Foundation Medicine test.
The group said the recommendations aim to standardize and improve warfarin response genotyping assays.
The deal marks the 10th distribution agreement Australia-based Sienna has signed for its test, including one covering Finland earlier this year.
The company had received CE marking for the test in April, allowing for its use as a clinical diagnostic test in Europe.
The company will use the funds to increase manufacturing, supply, and testing capacity for the SARS-CoV-2 test it launched in March.
The company posted Q1 revenues of $15.7 million, up from $12.3 million in Q1 2019 and above the consensus Wall Street estimate of $13.3 million.
The firm reported total revenues of $164 million, which was below the consensus Wall Street estimate of $167.2 million.
The San Francisco-based firm reported $64.2 million in revenues, up from $40.6 million a year ago and beating the average Wall Street estimate of $59.4 million.
In the quarter T2 signed a licensing agreement for SARS-CoV-2 assay development and a purchasing agreement with Vizient.
The company's Diagnostics segment was down 2 percent year over year, while its Discovery & Analytical Solutions segment grew 2 percent.
NG Biotech's COVID-19 NG-Test IgG-IgM test detects and differentiates the presence of isotypes IgG and IgG antibodies to SARS-CoV-2.
Both RT-PCR tests are designed to detect SARS-CoV-2 nucleic acid in nasal swabs, although Sansure's test can be used with other respiratory specimens.
The added funds will be used by Tangen to develop a molecular diagnostic platform to detect anthrax in the bloodstream and develop infectious disease tests.
The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.
The test will be included in the World Health Organizations list of prequalified in vitro diagnostics and UN agencies will be able to procure it.
The drugmaker will cover the cost of testing for up to 500 patients in the US with MSI-high colorectal cancer or RAI-refractory differentiated thyroid cancer.